314 related articles for article (PubMed ID: 30012187)
1. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
Schaub F; Hoerster R; Schiller P; Felsch M; Kraus D; Zarrouk M; Kirchhof B; Fauser S
Trials; 2018 Jul; 19(1):384. PubMed ID: 30012187
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
Schaub F; Schiller P; Hoerster R; Kraus D; Holz FG; Guthoff R; Agostini H; Spitzer MS; Wiedemann P; Lommatzsch A; Boden KT; Dimopoulos S; Bemme S; Tamm S; Maier M; Roider J; Enders P; Altay L; Fauser S; Kirchhof B;
Ophthalmology; 2022 Oct; 129(10):1129-1141. PubMed ID: 35680097
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Sundaram V; Barsam A; Virgili G
Cochrane Database Syst Rev; 2010 Jul; (7):CD006421. PubMed ID: 20614445
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Sundaram V; Barsam A; Virgili G
Cochrane Database Syst Rev; 2013 Jan; (1):CD006421. PubMed ID: 23440808
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
Asaria RH; Kon CH; Bunce C; Charteris DG; Wong D; Khaw PT; Aylward GW
Ophthalmology; 2001 Jul; 108(7):1179-83. PubMed ID: 11425671
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy.
Wickham L; Bunce C; Wong D; McGurn D; Charteris DG
Ophthalmology; 2007 Apr; 114(4):698-704. PubMed ID: 17398320
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Injection of Bevacizumab for the Prevention of Postoperative Proliferative Vitreoretinopathy in High-Risk Patients Selected by Laser Flare Photometry.
Gahon M; Luc A; Zessler A; Pastor G; Angioi-Duprez K; Thilly N; Berrod JP; Conart JB
Ophthalmologica; 2023; 246(5-6):306-313. PubMed ID: 37769629
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) in high-risk pediatric retinal detachment; randomized clinical trial.
Nasr M; Abdelhadi A; Bessa A; Ibrahim TM
BMC Ophthalmol; 2024 Mar; 24(1):97. PubMed ID: 38433191
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
Charteris DG; Aylward GW; Wong D; Groenewald C; Asaria RH; Bunce C;
Ophthalmology; 2004 Dec; 111(12):2240-5. PubMed ID: 15582080
[TBL] [Abstract][Full Text] [Related]
10. Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C.
Garcia RA; Sanchez JG; Arevalo JF
Ophthalmic Surg Lasers Imaging; 2007; 38(4):276-82. PubMed ID: 17674917
[TBL] [Abstract][Full Text] [Related]
11. Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis.
Shi H; Guo T; Liu PC; Wang QY; Du YR; Liu QY; He MM; Liu JL; Yu J
Drug Des Devel Ther; 2015; 9():1393-400. PubMed ID: 25834397
[TBL] [Abstract][Full Text] [Related]
12. Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial.
Banerjee PJ; Quartilho A; Bunce C; Xing W; Zvobgo TM; Harris N; Charteris DG
Ophthalmology; 2017 Jun; 124(6):757-767. PubMed ID: 28237428
[TBL] [Abstract][Full Text] [Related]
13. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.
Ghasemi Falavarjani K; Hashemi M; Modarres M; Hadavand Khani A
Eye (Lond); 2014 May; 28(5):576-80. PubMed ID: 24556886
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal methotrexate infusion for prophylaxis of proliferative vitreoretinopathy after pars plana vitrectomy for rhegmatogenous retinal detachment.
Fouad Aziz JH; Abd Al-Hakim Zaki M; Abd El-Fattah El-Shazly A; Mamoun T; Abdel Ghaffar Helmy RO; Hashem MH
Med Hypothesis Discov Innov Ophthalmol; 2022; 11(3):95-103. PubMed ID: 37641640
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy.
Schiff WM; Hwang JC; Ober MD; Olson JL; Dhrami-Gavazi E; Barile GR; Chang S; Mandava N
Arch Ophthalmol; 2007 Sep; 125(9):1161-7. PubMed ID: 17846353
[TBL] [Abstract][Full Text] [Related]
16. [Laser flare photometry for identification of high-risk patients for proliferative vitreoretinopathy].
Schaub F; Fauser S; Kirchhof B; Witte A; Hörster R
Ophthalmologe; 2018 Dec; 115(12):1079-1083. PubMed ID: 30151741
[TBL] [Abstract][Full Text] [Related]
17. Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy.
Storey P; Alshareef R; Khuthaila M; London N; Leiby B; DeCroos C; Kaiser R;
Retina; 2014 Oct; 34(10):1945-51. PubMed ID: 24999720
[TBL] [Abstract][Full Text] [Related]
18. Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes.
Wickham L; Ho-Yen GO; Bunce C; Wong D; Charteris DG
Br J Ophthalmol; 2011 Sep; 95(9):1234-8. PubMed ID: 21156702
[TBL] [Abstract][Full Text] [Related]
19. Inferior retinotomy and silicone oil tamponade for recurrent inferior retinal detachment and grade C PVR in eyes previously treated with pars plana vitrectomy or scleral buckle.
Mancino R; Aiello F; Ciuffoletti E; Di Carlo E; Cerulli A; Nucci C
BMC Ophthalmol; 2015 Dec; 15():173. PubMed ID: 26645589
[TBL] [Abstract][Full Text] [Related]
20. [Proliferative vitreoretinopathy: prophylactic treatment].
Chiquet C; Rouberol F
J Fr Ophtalmol; 2014 Nov; 37(9):737-43. PubMed ID: 25012973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
